

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

1. Name and Address of Reporting Person * <u>COLUMN GROUP II, LP</u>  (Last) (First) (Middle) 1700 OWENS STREET SUITE 500  (Street) SAN FRANCISCO CA 94158  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oric Pharmaceuticals, Inc. [ ORIC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/28/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/28/2020		C		3,500,000	A	(1)	3,575,000	D (2)	
Common Stock	04/28/2020		C		625,000	A	(1)	4,200,000	D (2)	
Common Stock	04/28/2020		C		416,666	A	(1)	4,616,666	D (2)	
Common Stock	04/28/2020		C		151,515	A	(1)	4,768,181	D (2)	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	04/28/2020		C		3,500,000		(1)	(1)	Common Stock	3,500,000	\$ 0.00	0	D (2)	
Series B Preferred Stock	(1)	04/28/2020		C		625,000		(1)	(1)	Common Stock	625,000	\$ 0.00	0	D (2)	
Series C Preferred Stock	(1)	04/28/2020		C		416,666		(1)	(1)	Common Stock	416,666	\$ 0.00	0	D (2)	
Series D Preferred Stock	(1)	04/28/2020		C		151,515		(1)	(1)	Common Stock	151,515	\$ 0.00	0	D (2)	

1. Name and Address of Reporting Person \*  
COLUMN GROUP II, LP  
 (Last) (First) (Middle)  
 1700 OWENS STREET  
 SUITE 500  
 (Street)  
 SAN FRANCISCO CA 94158  
 (City) (State) (Zip)

1. Name and Address of Reporting Person \*  
Column Group II GP, LP  
 (Last) (First) (Middle)  
 1700 OWENS STREET  
 SUITE 500  
 (Street)  
 SAN FRANCISCO CA 94158  
 (City) (State) (Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
<u>GOEDEL DAVID V</u>		
(Last)	(First)	(Middle)
1700 OWENS STREET		
SUITE 500		
(Street)		
SAN FRANCISCO CA		94158
(City)	(State)	(Zip)

**Explanation of Responses:**

- Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.
- The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goedel and Peter Svenilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

**Remarks:**

/s/ Jennifer J. Carlson, Attorney-in-Fact      04/28/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**